



Clinical trial results:

A Phase 1b/2 Study with Gemcitabine and LY2157299 for Patients with Metastatic Cancer (Phase 1b) and Advanced or Metastatic Unresectable Pancreatic Cancer (Phase 2)

Summary

EudraCT number	2011-000211-64
Trial protocol	ES BE DE IT
Global end of trial date	09 February 2016

Results information

Result version number	v1 (current)
This version publication date	05 January 2018
First version publication date	05 January 2018

Trial information

Trial identification

Sponsor protocol code	H9H-MC-JBAJ
-----------------------	-------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01373164
WHO universal trial number (UTN)	-
Other trial identifiers	Trial Alias: 13663

Notes:

Sponsors

Sponsor organisation name	Eli Lilly and Company
Sponsor organisation address	Lilly Corporate Center, Indianapolis, IN, United States, 46285
Public contact	Available Mon - Fri 9 AM - 5 PM EST, Eli Lilly and Company, 1 877CTLilly,
Scientific contact	Available Mon - Fri 9 AM - 5 PM EST, Eli Lilly and Company, 1 8772854559,

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	09 February 2016
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	09 February 2016
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

Phase 1b: To determine the safe and tolerable dose of galunisertib in combination with gemcitabine in patients with solid malignancy

Phase 2a: To compare the overall survival (OS) of patients with Stage II to IV unresectable pancreatic cancer when treated with a combination of galunisertib and gemcitabine with that of gemcitabine plus placebo.

Protection of trial subjects:

This study was conducted in accordance with International Conference on Harmonization (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the country or countries in which a study is conducted.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	07 June 2011
Long term follow-up planned	Yes
Long term follow-up rationale	Safety, Efficacy
Long term follow-up duration	1 Months
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects**Subjects enrolled per country**

Country: Number of subjects enrolled	Belgium: 6
Country: Number of subjects enrolled	United States: 19
Country: Number of subjects enrolled	Italy: 33
Country: Number of subjects enrolled	France: 30
Country: Number of subjects enrolled	Germany: 36
Country: Number of subjects enrolled	Spain: 45
Worldwide total number of subjects	169
EEA total number of subjects	150

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37	0

wk	
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	65
From 65 to 84 years	104
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Completers included participants who died from any cause and participants who were alive and on study (either on study treatment or in long term follow-up) at study conclusion.

Period 1

Period 1 title	Overall Study
Is this the baseline period?	No
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Phase 1b: 80 mg (milligrams) Galunisertib + Gemcitabine

Arm description:

Cohort 1: 40 mg Galunisertib was administered orally twice daily (BID) for 14 days followed by 14 days of rest (28 day cycle).

Gemcitabine at a dose of 1000 mg/m² (milligrams per square meter) was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

Arm type	Experimental
Investigational medicinal product name	Gemcitabine
Investigational medicinal product code	
Other name	Gemzar
Pharmaceutical forms	Powder for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Gemcitabine at a dose of 1000 mg/m² was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

Investigational medicinal product name	Galunisertib
Investigational medicinal product code	LY2157299
Other name	
Pharmaceutical forms	Coated tablet
Routes of administration	Oral use

Dosage and administration details:

40 mg Galunisertib was administered orally twice daily (BID) for 14 days followed by 14 days of rest (28 day cycle).

Arm title	Phase 1b: 160 mg Galunisertib + Gemcitabine
------------------	---

Arm description:

Cohort 2: 80 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).

Gemcitabine at a dose of 1000 mg/m² was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Galunisertib
Investigational medicinal product code	LY2157299
Other name	
Pharmaceutical forms	Coated tablet
Routes of administration	Oral use

Dosage and administration details:

80 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).

Investigational medicinal product name	Gemcitabine
Investigational medicinal product code	
Other name	Gemzar
Pharmaceutical forms	Powder for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Gemcitabine at a dose of 1000 mg/m² was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

Arm title	Phase 1b: 300 mg Galunisertib + Gemcitabine
------------------	---

Arm description:

Cohort 3: 150 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).

Gemcitabine at a dose of 1000 mg/m² was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

Arm type	Experimental
Investigational medicinal product name	Gemcitabine
Investigational medicinal product code	
Other name	Gemzar
Pharmaceutical forms	Powder for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Gemcitabine at a dose of 1000 mg/m² was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

Investigational medicinal product name	Galunisertib
Investigational medicinal product code	LY2157299
Other name	
Pharmaceutical forms	Coated tablet
Routes of administration	Oral use

Dosage and administration details:

150 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).

Arm title	Phase 2: 300 mg Galunisertib + Gemcitabine
------------------	--

Arm description:

Galunisertib recommended dose (300 mg) determined from phase 1, administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).

Gemcitabine at a dose of 1000 mg/m² was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

Arm type	Experimental
Investigational medicinal product name	Gemcitabine
Investigational medicinal product code	
Other name	Gemzar
Pharmaceutical forms	Powder for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Gemcitabine at a dose of 1000 mg/m² was administered intravenously once per week for 7 weeks

followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

Investigational medicinal product name	Galunisertib
Investigational medicinal product code	LY2157299
Other name	
Pharmaceutical forms	Coated tablet
Routes of administration	Oral use

Dosage and administration details:

150 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).

Arm title	Phase 2: Placebo + Gemcitabine
------------------	--------------------------------

Arm description:

Placebo administered orally twice daily for 14 days followed 14 days of rest (28 day cycle).

Gemcitabine at a dose of 1000 mg/m² was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

Arm type	Active comparator
Investigational medicinal product name	Gemcitabine
Investigational medicinal product code	
Other name	Gemzar
Pharmaceutical forms	Powder for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Gemcitabine at a dose of 1000 mg/m² was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Placebo administered orally twice daily for 14 days followed 14 days of rest (28 day cycle).

Number of subjects in period 1	Phase 1b: 80 mg (milligrams) Galunisertib + Gemcitabine	Phase 1b: 160 mg Galunisertib + Gemcitabine	Phase 1b: 300 mg Galunisertib + Gemcitabine
Started	5	4	5
Received at least one dose	5	4	5
Completed	5	3	4
Not completed	0	1	1
Consent withdrawn by subject	-	1	-
Lost to follow-up	-	-	1

Number of subjects in period 1	Phase 2: 300 mg Galunisertib + Gemcitabine	Phase 2: Placebo + Gemcitabine
Started	104	52
Received at least one dose	103	52
Completed	92	50
Not completed	12	2

Consent withdrawn by subject	10	2
Lost to follow-up	2	-

Period 2

Period 2 title	Received at Least One Dose
Is this the baseline period?	Yes ^[1]
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	No
Arm title	Phase 1b: 80 mg Galunisertib + Gemcitabine

Arm description:

Cohort 1: 40 mg Galunisertib was administered orally twice daily (BID) for 14 days followed by 14 days of rest (28 day cycle).

Gemcitabine at a dose of 1000 mg/m² was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

Arm type	Experimental
Investigational medicinal product name	Gemcitabine
Investigational medicinal product code	
Other name	Gemzar
Pharmaceutical forms	Powder for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Gemcitabine at a dose of 1000 mg/m² was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

Investigational medicinal product name	Galunisertib
Investigational medicinal product code	LY2157299
Other name	
Pharmaceutical forms	Coated tablet
Routes of administration	Oral use

Dosage and administration details:

40 mg Galunisertib was administered orally twice daily (BID) for 14 days followed by 14 days of rest (28 day cycle).

Arm title	Phase 1b: 160 mg Galunisertib + Gemcitabine
------------------	---

Arm description:

Cohort 2: 80 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).

Gemcitabine at a dose of 1000 mg/m² was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

Arm type	Experimental
Investigational medicinal product name	Galunisertib
Investigational medicinal product code	LY2157299
Other name	
Pharmaceutical forms	Coated tablet
Routes of administration	Oral use

Dosage and administration details:

80 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).

Investigational medicinal product name	Gemcitabine
Investigational medicinal product code	
Other name	Gemzar
Pharmaceutical forms	Powder for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Gemcitabine at a dose of 1000 mg/m² was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

Arm title	Phase 1b: 300 mg Galunisertib + Gemcitabine
------------------	---

Arm description:

Cohort 3: 150 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).

Gemcitabine at a dose of 1000 mg/m² was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

Arm type	Experimental
Investigational medicinal product name	Galunisertib
Investigational medicinal product code	LY2157299
Other name	
Pharmaceutical forms	Coated tablet
Routes of administration	Oral use

Dosage and administration details:

150 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).

Investigational medicinal product name	Gemcitabine
Investigational medicinal product code	
Other name	Gemzar
Pharmaceutical forms	Powder for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Gemcitabine at a dose of 1000 mg/m² was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

Arm title	Phase 2: 300 mg Galunisertib + Gemcitabine
------------------	--

Arm description:

Galunisertib recommended dose (300 mg) determined from phase 1, administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).

Gemcitabine at a dose of 1000 mg/m² was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

Arm type	Experimental
Investigational medicinal product name	Gemcitabine
Investigational medicinal product code	
Other name	Gemzar
Pharmaceutical forms	Powder for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Gemcitabine at a dose of 1000 mg/m² was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

Investigational medicinal product name	Galunisertib
Investigational medicinal product code	LY2157299
Other name	
Pharmaceutical forms	Coated tablet
Routes of administration	Oral use

Dosage and administration details:

150 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).

Arm title	Phase 2: Placebo + Gemcitabine
------------------	--------------------------------

Arm description:

Placebo administered orally twice daily for 14 days followed 14 days of rest (28 day cycle).
Gemcitabine at a dose of 1000 mg/m² was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

Arm type	Experimental
Investigational medicinal product name	Gemcitabine
Investigational medicinal product code	
Other name	Gemzar
Pharmaceutical forms	Powder for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Gemcitabine at a dose of 1000 mg/m² was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Placebo administered orally twice daily for 14 days followed 14 days of rest (28 day cycle).

Notes:

[1] - Period 1 is not the baseline period. It is expected that period 1 will be the baseline period.

Justification: The baseline characteristics are calculated for participants who received at least one dose of study drug as per SAP.

Number of subjects in period 2	Phase 1b: 80 mg Galunisertib + Gemcitabine	Phase 1b: 160 mg Galunisertib + Gemcitabine	Phase 1b: 300 mg Galunisertib + Gemcitabine
Started	5	4	5
Completed	5	3	4
Not completed	0	1	1
Consent withdrawn by subject	-	1	-
Lost to follow-up	-	-	1

Number of subjects in period 2	Phase 2: 300 mg Galunisertib + Gemcitabine	Phase 2: Placebo + Gemcitabine
Started	103	52
Completed	92	50
Not completed	11	2
Consent withdrawn by subject	9	2
Lost to follow-up	2	-

Baseline characteristics

Reporting groups

Reporting group title	Phase 1b: 80 mg Galunisertib + Gemcitabine
Reporting group description:	
Cohort 1: 40 mg Galunisertib was administered orally twice daily (BID) for 14 days followed by 14 days of rest (28 day cycle).	
Gemcitabine at a dose of 1000 mg/m ² was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.	
Reporting group title	Phase 1b: 160 mg Galunisertib + Gemcitabine
Reporting group description:	
Cohort 2: 80 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).	
Gemcitabine at a dose of 1000 mg/m ² was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.	
Reporting group title	Phase 1b: 300 mg Galunisertib + Gemcitabine
Reporting group description:	
Cohort 3: 150 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).	
Gemcitabine at a dose of 1000 mg/m ² was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.	
Reporting group title	Phase 2: 300 mg Galunisertib + Gemcitabine
Reporting group description:	
Galunisertib recommended dose (300 mg) determined from phase 1, administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).	
Gemcitabine at a dose of 1000 mg/m ² was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.	
Reporting group title	Phase 2: Placebo + Gemcitabine
Reporting group description:	
Placebo administered orally twice daily for 14 days followed 14 days of rest (28 day cycle).	
Gemcitabine at a dose of 1000 mg/m ² was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.	

Reporting group values	Phase 1b: 80 mg Galunisertib + Gemcitabine	Phase 1b: 160 mg Galunisertib + Gemcitabine	Phase 1b: 300 mg Galunisertib + Gemcitabine
Number of subjects	5	4	5
Age categorical			
Units: Subjects			
In utero			
Preterm newborn infants (gestational age < 37 wks)			
Newborns (0-27 days)			
Infants and toddlers (28 days-23 months)			
Children (2-11 years)			
Adolescents (12-17 years)			
Adults (18-64 years)			
From 65-84 years			
85 years and over			
Age Continuous			
Units: Years			
arithmetic mean	63.2	63.8	56.6
standard deviation	± 12.9	± 9.0	± 9.2

Gender categorical Units: Subjects			
Female	0	3	3
Male	5	1	2
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	0	0	1
Not Hispanic or Latino	5	4	4
Unknown or Not Reported	0	0	0
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	2	0	0
White	3	4	5
More than one race	0	0	0
Unknown or Not Reported	0	0	0
Region of Enrollment Units: Subjects			
Belgium	0	0	0
United States	5	2	1
Italy	0	0	0
France	0	0	0
Germany	0	0	0
Spain	0	2	4

Reporting group values	Phase 2: 300 mg Galunisertib + Gemcitabine	Phase 2: Placebo + Gemcitabine	Total
Number of subjects	103	52	169
Age categorical Units: Subjects			
In utero			
Preterm newborn infants (gestational age < 37 wks)			
Newborns (0-27 days)			
Infants and toddlers (28 days-23 months)			
Children (2-11 years)			
Adolescents (12-17 years)			
Adults (18-64 years)			
From 65-84 years			
85 years and over			
Age Continuous Units: Years			
arithmetic mean	67.3	66.3	
standard deviation	± 8.2	± 8.9	-
Gender categorical Units: Subjects			
Female	46	24	76
Male	57	28	93

Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	0	0	1
Not Hispanic or Latino	37	18	68
Unknown or Not Reported	66	34	100
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	2
White	95	50	157
More than one race	0	0	0
Unknown or Not Reported	8	2	10
Region of Enrollment			
Units: Subjects			
Belgium	4	2	6
United States	7	4	19
Italy	23	10	33
France	21	9	30
Germany	22	14	36
Spain	26	13	45

End points

End points reporting groups

Reporting group title	Phase 1b: 80 mg (milligrams) Galunisertib + Gemcitabine
-----------------------	---

Reporting group description:

Cohort 1: 40 mg Galunisertib was administered orally twice daily (BID) for 14 days followed by 14 days of rest (28 day cycle).

Gemcitabine at a dose of 1000 mg/m² (milligrams per square meter) was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

Reporting group title	Phase 1b: 160 mg Galunisertib + Gemcitabine
-----------------------	---

Reporting group description:

Cohort 2: 80 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).

Gemcitabine at a dose of 1000 mg/m² was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

Reporting group title	Phase 1b: 300 mg Galunisertib + Gemcitabine
-----------------------	---

Reporting group description:

Cohort 3: 150 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).

Gemcitabine at a dose of 1000 mg/m² was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

Reporting group title	Phase 2: 300 mg Galunisertib + Gemcitabine
-----------------------	--

Reporting group description:

Galunisertib recommended dose (300 mg) determined from phase 1, administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).

Gemcitabine at a dose of 1000 mg/m² was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

Reporting group title	Phase 2: Placebo + Gemcitabine
-----------------------	--------------------------------

Reporting group description:

Placebo administered orally twice daily for 14 days followed 14 days of rest (28 day cycle).

Gemcitabine at a dose of 1000 mg/m² was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

Reporting group title	Phase 1b: 80 mg Galunisertib + Gemcitabine
-----------------------	--

Reporting group description:

Cohort 1: 40 mg Galunisertib was administered orally twice daily (BID) for 14 days followed by 14 days of rest (28 day cycle).

Gemcitabine at a dose of 1000 mg/m² was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

Reporting group title	Phase 1b: 160 mg Galunisertib + Gemcitabine
-----------------------	---

Reporting group description:

Cohort 2: 80 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).

Gemcitabine at a dose of 1000 mg/m² was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

Reporting group title	Phase 1b: 300 mg Galunisertib + Gemcitabine
-----------------------	---

Reporting group description:

Cohort 3: 150 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).

Gemcitabine at a dose of 1000 mg/m² was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

Reporting group title	Phase 2: 300 mg Galunisertib + Gemcitabine
-----------------------	--

Reporting group description:

Galunisertib recommended dose (300 mg) determined from phase 1, administered orally twice daily for

14 days followed by 14 days of rest (28 day cycle).

Gemcitabine at a dose of 1000 mg/m² was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

Reporting group title	Phase 2: Placebo + Gemcitabine
-----------------------	--------------------------------

Reporting group description:

Placebo administered orally twice daily for 14 days followed 14 days of rest (28 day cycle).

Gemcitabine at a dose of 1000 mg/m² was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

Subject analysis set title	Phase 1b Participants
----------------------------	-----------------------

Subject analysis set type	Intention-to-treat
---------------------------	--------------------

Subject analysis set description:

Participants received galunisertib at a starting dose of 80 mg/day in combination with gemcitabine. Dose escalation proceeded in cohorts of between 3 to 6 evaluable participants until ≥ 2 participants experienced a dose limiting toxicity (DLT) or an galunisertib dose level of 300 mg/day was reached.

Primary: Phase 1b: Recommended Phase 2 dose

End point title	Phase 1b: Recommended Phase 2 dose ^[1]
-----------------	---

End point description:

The recommended Phase 2 dose was the highest dose where less than 1/3 of participants experienced dose limiting toxicities (DLTs). The recommended dose was determined based on a review of overall toxicity, dose reductions, omissions, and pharmacokinetic information from Phase 1b.

Analysis Population Description: All participants who received at least one dose of study drug.

End point type	Primary
----------------	---------

End point timeframe:

Time of first phase 1b dose until time of last phase 1b dose (up to 1 year)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistics are being reported for all randomized participants per the protocol or Statistical Analysis Plan.

End point values	Phase 1b Participants			
Subject group type	Subject analysis set			
Number of subjects analysed	14			
Units: milligrams (mg)				
number (not applicable)	300			

Statistical analyses

No statistical analyses for this end point

Primary: Phase 2: Overall Survival (OS)

End point title	Phase 2: Overall Survival (OS)
-----------------	--------------------------------

End point description:

Overall survival is defined as the time from the date of randomization to the date of death from any cause. For each participant who is not known to have died as of the data-inclusion cut-off date for a particular analysis, overall survival duration was censored for that analysis at the date of last prior contact.

Analysis Population Description: All randomized participants who received at least one dose of study drug and had baseline & at least one post baseline observation. Number of participants censored were Galunisertib + Gemcitabine = 20 and Placebo + Gemcitabine = 4.

End point type	Primary
----------------	---------

End point timeframe:

Baseline to date of death from any cause (up to 2 years)

End point values	Phase 2: 300 mg Galunisertib + Gemcitabine	Phase 2: Placebo + Gemcitabine		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	104	52		
Units: Months				
median (confidence interval 95%)	8.9 (7.3 to 11.1)	7.1 (5.8 to 9.0)		

Statistical analyses

Statistical analysis title	STATISTICAL_ANALYSIS_TITLE
Comparison groups	Phase 2: 300 mg Galunisertib + Gemcitabine v Phase 2: Placebo + Gemcitabine
Number of subjects included in analysis	156
Analysis specification	Pre-specified
Analysis type	superiority ^[2]
Method	Bayesian Analysis
Parameter estimate	Hazard ratio (HR)
Point estimate	0.794
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.59
upper limit	1.085

Notes:

[2] - The planned primary analysis for this study utilized a Bayesian exponential-likelihood model, incorporating historical overall survival (OS) data from 2 studies (Oettle et al. 2005; Saif et al. 2009). The primary analysis was performed using strong borrowing from the historical data. The model was estimated to borrow approximately 37 events from the historical studies.

Secondary: Phase 1b: Pharmacokinetics: Area Under the Concentration-Time Curve at steady state From Time Zero to 24 Hours (AUC[0-24], ss) and Time Zero to Infinity (AUC[0-∞], ss)

End point title	Phase 1b: Pharmacokinetics: Area Under the Concentration-Time Curve at steady state From Time Zero to 24 Hours (AUC[0-24], ss) and Time Zero to Infinity (AUC[0-∞], ss)
-----------------	---

End point description:

For Arm: Phase 1b: 160 mg Galunisertib + Gemcitabine, the geometric mean and geometric coefficient of variation was not analyzed.

Analysis Population Description: Phase 1b: All participants who received at least one dose of study drug and had evaluable PK data.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1 Days 14 (predose; 0.5, 2, 3, and 6 hours post dose), Days 15 and 16 (predose)

End point values	Phase 1b: 80 mg (milligrams) Galunisertib + Gemcitabine	Phase 1b: 300 mg Galunisertib + Gemcitabine		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	3		
Units: nanogram*hour per milliliter (ng*h/mL)				
geometric mean (geometric coefficient of variation)				
AUC(0-24)	2530 (± 116)	9090 (± 27)		
AUC(0-∞)	2740 (± 117)	10600 (± 10)		

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 1b: Pharmacokinetics: maximum plasma drug concentration at steady state (C_{max,ss})

End point title	Phase 1b: Pharmacokinetics: maximum plasma drug concentration at steady state (C _{max,ss})
-----------------	--

End point description:

For arm 160 mg Galunisertib + Gemcitabine, the geometric mean and geometric coefficient of variation were not analyzed.

Analysis Population Description: Phase 1b: All participants who received at least one dose of study drug and had evaluable PK data.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1: Days 14 (predose; 0.5, 2, 3, and 6 hours post dose), Days 15 and 16 (predose)

End point values	Phase 1b: 80 mg (milligrams) Galunisertib + Gemcitabine	Phase 1b: 300 mg Galunisertib + Gemcitabine		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	3		
Units: nanogram per milliliter (ng/mL)				
geometric mean (geometric coefficient of variation)	385 (± 101)	1050 (± 39)		

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 1b: Number of participants with tumor response

End point title	Phase 1b: Number of participants with tumor response
-----------------	--

End point description:

Response was defined using RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1. Complete Response (CR) was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 millimeter (mm) and normalization of tumor marker level of non-target lesions; Partial Response (PR) was defined as having at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD) was defined as having at least 20% increase in sum of longest diameter of target lesions and minimum 5 mm increase above nadir; Stable Disease (SD) was defined as small changes that did not meet above criteria.

Analysis Population Description: Phase 1b: All participants who received at least one dose of study drug.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to end of Phase 1b (up to 1 year)

End point values	Phase 1b: 80 mg (milligrams) Galunisertib + Gemcitabine	Phase 1b: 160 mg Galunisertib + Gemcitabine	Phase 1b: 300 mg Galunisertib + Gemcitabine	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	4	5	
Units: Participants				
number (not applicable)				
Progressive Disease (PD)	3	1	2	
Stable Disease (SD)	1	2	2	
Partial Response (PR)	0	1	0	
Non-Complete Response/Non-Progressive Disease (NC)	0	0	1	
Not Assessed (NA)	1	0	0	

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 2: Progression Free Survival (PFS)

End point title	Phase 2: Progression Free Survival (PFS)
-----------------	--

End point description:

PFS is defined as the date of randomization to the first date of progression of disease or of death from any cause. For each participant who is not known to have died or to have had a progression of disease as of the data-inclusion cut-off date for a particular analysis, PFS will be censored at the date of last prior contact. PFS will be calculated and analyzed twice: (1) including clinical progressions of disease not based on lesion measurements, and (2) excluding clinical progressions. Progression Disease (PD) was defined as having at least a 25% increase in the sum of the longest diameter of target lesions.

Analysis Population Description: All randomized participants who received at least one dose of study drug and had baseline & at least one post baseline observation. Number of participants censored were Galunisertib + Gemcitabine = 21 and Placebo + Gemcitabine = 11.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to first date of progressive disease or death due to any cause (up to 2 years)

End point values	Phase 2: 300 mg Galunisertib + Gemcitabine	Phase 2: Placebo + Gemcitabine		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	104	52		
Units: Months				
median (confidence interval 95%)	4.11 (2.66 to 5.42)	2.86 (1.94 to 3.75)		

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 2: Percentage change from baseline in tumor size (CTS)

End point title	Phase 2: Percentage change from baseline in tumor size (CTS)
-----------------	--

End point description:

Change in tumor size is defined as the maximum percent change from baseline in the sum of target lesions. Change was assessed in each participant using radiographic imaging.

Analysis Population Description: All randomized participants who received at least 1 dose of study drug and had baseline and a post-baseline measurement for change in tumor size.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, end of Cycle 2

End point values	Phase 2: 300 mg Galunisertib + Gemcitabine	Phase 2: Placebo + Gemcitabine		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	104	52		
Units: Percent change in tumor size				
geometric mean (confidence interval 95%)				
Independent Assessor 1	0.95 (0.90 to 1.01)	0.92 (0.87 to 0.98)		
Independent Assessor 2	1.03 (0.95 to 1.11)	0.98 (0.92 to 1.05)		

Statistical analyses

Secondary: Phase 2: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate[ORR]) as Assessed by Independent Central Reviewers

End point title	Phase 2: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate[ORR]) as Assessed by Independent Central Reviewers
-----------------	---

End point description:

Overall response rate is the best response of complete response (CR) or partial response (PR) as classified by the independent central review according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with at least 1 measurable lesion, multiplied by 100.

Analysis Population Description: All randomized participants who received at least 1 dose of study drug and had baseline and a post-baseline measurement for ORR.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to measured progressive disease (up to 2 years)

End point values	Phase 2: 300 mg Galunisertib + Gemcitabine	Phase 2: Placebo + Gemcitabine		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	104	52		
Units: Percentage of Participants				
number (confidence interval 95%)	10.6 (5.4 to 18.1)	3.8 (0.5 to 13.2)		

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 2: Population Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Time Zero to 24 Hours (AUC[0-24])

End point title	Phase 2: Population Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Time Zero to 24 Hours (AUC[0-24])
-----------------	---

End point description:

Analysis Population Description: Phase 2: All randomized participants who received at least 1 dose of study drug with evaluable PK data.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1 Days 1 and 14, (predose; 0.5 to 2 hours, 3.5 to 5 hours post dose); Cycle 1 Day 7 (predose; 0.5 to 2 hours postdose); Cycle 1 Day 15, morning; Cycle 1 Day 16, morning

End point values	Phase 2: 300 mg Galunisertib + Gemcitabine			
Subject group type	Reporting group			
Number of subjects analysed	99			
Units: mg*h/L				
arithmetic mean (inter-quartile range (Q1-Q3))	5.56 (3.82 to 7.91)			

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 2: Population PK: Maximum Concentration (Cmax) of galunisertib

End point title	Phase 2: Population PK: Maximum Concentration (Cmax) of galunisertib
End point description: Analysis Population Description: Phase 2: All randomized participants who received at least 1 dose of study drug with evaluable PK data.	
End point type	Secondary
End point timeframe: Cycle 1 Days 1 and 14, (predose; 0.5 to 2 hours, 3.5 to 5 hours post dose); Cycle 1 Day 7 (predose; 0.5 to 2 hours postdose); Cycle 1 Day 15, morning; Cycle 1 Day 16, morning	

End point values	Phase 2: 300 mg Galunisertib + Gemcitabine			
Subject group type	Reporting group			
Number of subjects analysed	99			
Units: ng/mL				
arithmetic mean (inter-quartile range (Q1-Q3))	904 (668 to 1194)			

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 2: Change from baseline in Brief Pain Inventory-short form (BPI-sf) at study completion

End point title	Phase 2: Change from baseline in Brief Pain Inventory-short form (BPI-sf) at study completion
End point description: The BPI-SF Pain Severity Subscale was a participant-rated questionnaire that measured the severity of pain. Severity scores could have ranged from 0 (no pain) to 10 (pain as bad as you can imagine) for questions assessing worst pain, least pain, and average pain in the past 24 hours, and pain right now. The BPI-SF Interference Subscale measured the interference of pain with the participant's ability to function. Interference scores could have ranged from 0 (does not interfere) to 10 (completely interferes)	

for questions assessing interference of pain in the past 24 hours for general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life.

Analysis Population Description: All randomized participants who received at least 1 dose of study drug and had baseline and a post-baseline measurement for BPI-sf.

End point type	Secondary
End point timeframe:	
Baseline, study treatment completion (up to 1 year)	

End point values	Phase 2: 300 mg Galunisertib + Gemcitabine	Phase 2: Placebo + Gemcitabine		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	7	2		
Units: Units on a scale				
arithmetic mean (standard deviation)	2.54 (\pm 2.53)	1.50 (\pm 2.12)		

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 2: Change from baseline in carbohydrate antigen 19.9 (CA19-9) level at first study completion follow-up

End point title	Phase 2: Change from baseline in carbohydrate antigen 19.9 (CA19-9) level at first study completion follow-up
-----------------	---

End point description:

Carbohydrate antigen 19-9 (CA 19-9) is a modified Lewis(a) blood group antigen, and has been used as a tumor marker. The outcome measure is the median, minimum and maximum values from participants who had samples collected at baseline and at follow-up.

Analysis Population Description: All randomized participants who received at least 1 dose of study drug and had baseline and a post-baseline measurement for CA19-9 level.

End point type	Secondary
End point timeframe:	
Baseline, study treatment completion after first follow up visit (up to 1 year)	

End point values	Phase 2: 300 mg Galunisertib + Gemcitabine	Phase 2: Placebo + Gemcitabine		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	38	21		
Units: Units/Milliliter				
median (full range (min-max))	32.7 (-93.8 to 3636.3)	-33.3 (-98.1 to 2460.9)		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Up to 30 days

Adverse event reporting additional description:

All participants who received at least one dose of study drug.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	18.1
--------------------	------

Reporting groups

Reporting group title	Phase 1b: 80 mg LY2157299 + Gemcitabine
-----------------------	---

Reporting group description: -

Reporting group title	Phase 1b: 160 mg LY2157299 + Gemcitabine
-----------------------	--

Reporting group description: -

Reporting group title	Phase 1b: 300 mg LY2157299 + Gemcitabine
-----------------------	--

Reporting group description: -

Reporting group title	Phase 2: 300 mg LY2157299 + Gemcitabine
-----------------------	---

Reporting group description: -

Reporting group title	Phase 2: Placebo + Gemcitabine
-----------------------	--------------------------------

Reporting group description: -

Serious adverse events	Phase 1b: 80 mg LY2157299 + Gemcitabine	Phase 1b: 160 mg LY2157299 + Gemcitabine	Phase 1b: 300 mg LY2157299 + Gemcitabine
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 5 (20.00%)	1 / 4 (25.00%)	2 / 5 (40.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
malignant ascites			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 5 (20.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
tumour pain			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Vascular disorders			
orthostatic hypotension			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
shock haemorrhagic			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
pancreatic pseudocyst drainage			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
asthenia			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
fatigue			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
general physical health deterioration			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
multi-organ failure			

alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
oedema peripheral			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pain			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pyrexia			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
dyspnoea			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
haemothorax			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pleural effusion			
alternative dictionary used: MedDRA 18.1			

subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pneumonitis			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pneumothorax			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pulmonary embolism			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pulmonary hypertension			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
respiratory distress			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
respiratory failure			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Psychiatric disorders			
agitation			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
confusional state			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
delirium			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device occlusion			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
blood bilirubin increased			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
blood creatinine increased			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			

fall			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
femur fracture			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
gastrointestinal stoma complication			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
humerus fracture			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
lower limb fracture			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
toxicity to various agents			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
angina pectoris			
alternative dictionary used: MedDRA 18.1			

subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cardiac failure			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cardiogenic shock			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
myocardial ischaemia			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pericardial effusion			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
cerebral ischaemia			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cerebrovascular accident			
alternative dictionary used: MedDRA 18.1			

subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
disturbance in attention alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hepatic encephalopathy alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ischaemic stroke alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
presyncope alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
syncope alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
abdominal pain alternative dictionary used: MedDRA 18.1			

subjects affected / exposed	0 / 5 (0.00%)	1 / 4 (25.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
abdominal pain upper			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ascites			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
colitis ischaemic			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
constipation			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
diarrhoea			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
duodenal obstruction			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

duodenal stenosis				
alternative dictionary used: MedDRA 18.1				
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
femoral hernia incarcerated				
alternative dictionary used: MedDRA 18.1				
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
gastric ulcer				
alternative dictionary used: MedDRA 18.1				
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
gastrointestinal haemorrhage				
alternative dictionary used: MedDRA 18.1				
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
haematemesis				
alternative dictionary used: MedDRA 18.1				
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
ileus paralytic				
alternative dictionary used: MedDRA 18.1				
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	
intestinal obstruction				
alternative dictionary used: MedDRA 18.1				

subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
large intestinal obstruction alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 5 (20.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
lower gastrointestinal haemorrhage alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
melaena alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
nausea alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
obstruction gastric alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
oesophagitis alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

pancreatitis acute alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
small intestinal obstruction alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
upper gastrointestinal haemorrhage alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
vomiting alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
bile duct obstruction alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
bile duct stenosis alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cholangitis alternative dictionary used: MedDRA 18.1			

subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cholangitis acute alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cholecystitis alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cholecystitis acute alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cholestasis alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hepatic cirrhosis alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hepatic failure alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

hepatocellular injury alternative dictionary used: MedDRA 18.1 subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
jaundice cholestatic alternative dictionary used: MedDRA 18.1 subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders acute kidney injury alternative dictionary used: MedDRA 18.1 subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
renal failure alternative dictionary used: MedDRA 18.1 subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ureteric stenosis alternative dictionary used: MedDRA 18.1 subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders osteoarthritis alternative dictionary used: MedDRA 18.1 subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
rhabdomyolysis			

alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 5 (20.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
biliary tract infection			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
bronchitis			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
catheter site infection			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cholecystitis infective			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
device related infection			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
endocarditis			
alternative dictionary used: MedDRA 18.1			

subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
infection			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
liver abscess			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
lung infection			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
peritonitis			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
peritonitis bacterial			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pneumonia			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

pyelonephritis			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
sepsis			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
staphylococcal infection			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
urinary tract infection			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
urosepsis			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
diabetes mellitus			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hyperglycaemia			
alternative dictionary used: MedDRA 18.1			

subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hyponatraemia			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Phase 2: 300 mg LY2157299 + Gemcitabine	Phase 2: Placebo + Gemcitabine	
Total subjects affected by serious adverse events			
subjects affected / exposed	56 / 103 (54.37%)	26 / 52 (50.00%)	
number of deaths (all causes)	7	5	
number of deaths resulting from adverse events	2	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
malignant ascites			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 103 (0.00%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
tumour pain			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
orthostatic hypotension			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 103 (0.00%)	1 / 52 (1.92%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
shock haemorrhagic			
alternative dictionary used: MedDRA 18.1			

subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Surgical and medical procedures			
pancreatic pseudocyst drainage			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 103 (0.00%)	1 / 52 (1.92%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
asthenia			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
fatigue			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 103 (0.00%)	1 / 52 (1.92%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
general physical health deterioration			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	2 / 103 (1.94%)	1 / 52 (1.92%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
multi-organ failure			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 103 (0.00%)	1 / 52 (1.92%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
oedema peripheral			
alternative dictionary used: MedDRA 18.1			

subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
pain			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
pyrexia			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	4 / 103 (3.88%)	3 / 52 (5.77%)	
occurrences causally related to treatment / all	1 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
dyspnoea			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	2 / 103 (1.94%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
haemothorax			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
pleural effusion			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 103 (0.00%)	1 / 52 (1.92%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
pneumonitis			
alternative dictionary used: MedDRA 18.1			

subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
pneumothorax			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
pulmonary embolism			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	5 / 103 (4.85%)	1 / 52 (1.92%)	
occurrences causally related to treatment / all	1 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
pulmonary hypertension			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 103 (0.00%)	1 / 52 (1.92%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
respiratory distress			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
respiratory failure			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Psychiatric disorders			
agitation			
alternative dictionary used: MedDRA 18.1			

subjects affected / exposed	0 / 103 (0.00%)	1 / 52 (1.92%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
confusional state			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
delirium			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 103 (0.00%)	1 / 52 (1.92%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device occlusion			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	3 / 103 (2.91%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
blood bilirubin increased			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
blood creatinine increased			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
fall			
alternative dictionary used: MedDRA 18.1			

subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
femur fracture			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 103 (0.00%)	1 / 52 (1.92%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
gastrointestinal stoma complication			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
humerus fracture			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 103 (0.00%)	1 / 52 (1.92%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
lower limb fracture			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
toxicity to various agents			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
Cardiac disorders			
angina pectoris			
alternative dictionary used: MedDRA 18.1			

subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
cardiac failure			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
cardiogenic shock			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
myocardial ischaemia			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
pericardial effusion			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
Nervous system disorders			
cerebral ischaemia			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
cerebrovascular accident			
alternative dictionary used: MedDRA 18.1			

subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
disturbance in attention alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 103 (0.00%)	1 / 52 (1.92%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
hepatic encephalopathy alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ischaemic stroke alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
presyncope alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 103 (0.00%)	1 / 52 (1.92%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
syncope alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	1 / 52 (1.92%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
abdominal pain alternative dictionary used: MedDRA 18.1			

subjects affected / exposed	5 / 103 (4.85%)	1 / 52 (1.92%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
abdominal pain upper			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 103 (0.00%)	1 / 52 (1.92%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ascites			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	1 / 52 (1.92%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
colitis ischaemic			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
constipation			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	1 / 52 (1.92%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
diarrhoea			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
duodenal obstruction			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

duodenal stenosis				
alternative dictionary used: MedDRA 18.1				
subjects affected / exposed	0 / 103 (0.00%)	1 / 52 (1.92%)		
occurrences causally related to treatment / all	0 / 0	0 / 1		
deaths causally related to treatment / all	0 / 0	0 / 0		
femoral hernia incarcerated				
alternative dictionary used: MedDRA 18.1				
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)		
occurrences causally related to treatment / all	0 / 1	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
gastric ulcer				
alternative dictionary used: MedDRA 18.1				
subjects affected / exposed	0 / 103 (0.00%)	1 / 52 (1.92%)		
occurrences causally related to treatment / all	0 / 0	0 / 1		
deaths causally related to treatment / all	0 / 0	0 / 0		
gastrointestinal haemorrhage				
alternative dictionary used: MedDRA 18.1				
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)		
occurrences causally related to treatment / all	0 / 2	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
haematemesis				
alternative dictionary used: MedDRA 18.1				
subjects affected / exposed	0 / 103 (0.00%)	1 / 52 (1.92%)		
occurrences causally related to treatment / all	0 / 0	0 / 1		
deaths causally related to treatment / all	0 / 0	0 / 0		
ileus paralytic				
alternative dictionary used: MedDRA 18.1				
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)		
occurrences causally related to treatment / all	0 / 1	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
intestinal obstruction				
alternative dictionary used: MedDRA 18.1				

subjects affected / exposed	1 / 103 (0.97%)	3 / 52 (5.77%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
large intestinal obstruction alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 103 (0.00%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
lower gastrointestinal haemorrhage alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
melaena alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
nausea alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	2 / 103 (1.94%)	2 / 52 (3.85%)	
occurrences causally related to treatment / all	2 / 2	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
obstruction gastric alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 103 (0.00%)	1 / 52 (1.92%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
oesophagitis alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 103 (0.00%)	1 / 52 (1.92%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

pancreatitis acute alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 103 (0.97%) 0 / 1 0 / 0	0 / 52 (0.00%) 0 / 0 0 / 0		
small intestinal obstruction alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	2 / 103 (1.94%) 0 / 2 0 / 0	0 / 52 (0.00%) 0 / 0 0 / 0		
upper gastrointestinal haemorrhage alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 103 (0.97%) 0 / 1 0 / 1	0 / 52 (0.00%) 0 / 0 0 / 0		
vomiting alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	4 / 103 (3.88%) 1 / 4 0 / 0	2 / 52 (3.85%) 0 / 2 0 / 0		
Hepatobiliary disorders bile duct obstruction alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 103 (0.00%) 0 / 0 0 / 0	1 / 52 (1.92%) 0 / 1 0 / 0		
bile duct stenosis alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	2 / 103 (1.94%) 0 / 3 0 / 0	1 / 52 (1.92%) 0 / 1 0 / 0		
cholangitis alternative dictionary used: MedDRA 18.1				

subjects affected / exposed	4 / 103 (3.88%)	2 / 52 (3.85%)	
occurrences causally related to treatment / all	0 / 7	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
cholangitis acute			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
cholecystitis			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
cholecystitis acute			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
cholestasis			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	1 / 52 (1.92%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
hepatic cirrhosis			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
hepatic failure			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

hepatocellular injury alternative dictionary used: MedDRA 18.1 subjects affected / exposed	0 / 103 (0.00%)	1 / 52 (1.92%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
jaundice cholestatic alternative dictionary used: MedDRA 18.1 subjects affected / exposed	3 / 103 (2.91%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
acute kidney injury alternative dictionary used: MedDRA 18.1 subjects affected / exposed	0 / 103 (0.00%)	1 / 52 (1.92%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
renal failure alternative dictionary used: MedDRA 18.1 subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ureteric stenosis alternative dictionary used: MedDRA 18.1 subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
osteoarthritis alternative dictionary used: MedDRA 18.1 subjects affected / exposed	0 / 103 (0.00%)	1 / 52 (1.92%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
rhabdomyolysis			

alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 103 (0.00%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
biliary tract infection			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
bronchitis			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
catheter site infection			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 103 (0.00%)	1 / 52 (1.92%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
cholecystitis infective			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
device related infection			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
endocarditis			
alternative dictionary used: MedDRA 18.1			

subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
infection			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 103 (0.00%)	1 / 52 (1.92%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
liver abscess			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
lung infection			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	2 / 103 (1.94%)	1 / 52 (1.92%)	
occurrences causally related to treatment / all	1 / 2	0 / 1	
deaths causally related to treatment / all	1 / 1	0 / 1	
peritonitis			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 103 (0.00%)	1 / 52 (1.92%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
peritonitis bacterial			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
pneumonia			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

pyelonephritis alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 103 (0.97%) 0 / 1 0 / 0	0 / 52 (0.00%) 0 / 0 0 / 0	
sepsis alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	2 / 103 (1.94%) 0 / 2 0 / 0	2 / 52 (3.85%) 1 / 2 0 / 1	
staphylococcal infection alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 103 (0.97%) 0 / 1 0 / 0	0 / 52 (0.00%) 0 / 0 0 / 0	
urinary tract infection alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 103 (0.97%) 0 / 1 0 / 0	1 / 52 (1.92%) 1 / 1 0 / 0	
urosepsis alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 103 (0.00%) 0 / 0 0 / 0	1 / 52 (1.92%) 0 / 1 0 / 0	
Metabolism and nutrition disorders diabetes mellitus alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 103 (0.97%) 0 / 1 0 / 0	0 / 52 (0.00%) 0 / 0 0 / 0	
hyperglycaemia alternative dictionary used: MedDRA 18.1			

subjects affected / exposed	0 / 103 (0.00%)	1 / 52 (1.92%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
hyponatraemia			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	0 / 52 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Phase 1b: 80 mg LY2157299 + Gemcitabine	Phase 1b: 160 mg LY2157299 + Gemcitabine	Phase 1b: 300 mg LY2157299 + Gemcitabine
Total subjects affected by non-serious adverse events			
subjects affected / exposed	5 / 5 (100.00%)	4 / 4 (100.00%)	5 / 5 (100.00%)
General disorders and administration site conditions			
asthenia			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	1 / 4 (25.00%)	3 / 5 (60.00%)
occurrences (all)	0	1	4
chills			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 5 (20.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	4	0	0
early satiety			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	1 / 4 (25.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
face oedema			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	1 / 4 (25.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
fatigue			
alternative dictionary used: MedDRA 18.1			

subjects affected / exposed	2 / 5 (40.00%)	2 / 4 (50.00%)	1 / 5 (20.00%)
occurrences (all)	2	4	1
localised oedema			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	1 / 4 (25.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
mucosal inflammation			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	2 / 5 (40.00%)
occurrences (all)	0	0	4
oedema peripheral			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 5 (20.00%)	2 / 4 (50.00%)	1 / 5 (20.00%)
occurrences (all)	1	2	1
pain			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 5 (20.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
peripheral swelling			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	1 / 4 (25.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
pyrexia			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 5 (20.00%)	3 / 4 (75.00%)	2 / 5 (40.00%)
occurrences (all)	3	8	4
Reproductive system and breast disorders			
pelvic pain			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	1 / 4 (25.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Respiratory, thoracic and mediastinal disorders			
cough			
alternative dictionary used: MedDRA 18.1			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>dyspnoea</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>epistaxis</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>oropharyngeal pain</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 5 (0.00%)</p> <p>0</p> <p>0 / 5 (0.00%)</p> <p>0</p> <p>0 / 5 (0.00%)</p> <p>0</p> <p>0 / 5 (0.00%)</p> <p>0</p> <p>0 / 5 (0.00%)</p> <p>0</p>	<p>0 / 4 (0.00%)</p> <p>0</p> <p>1 / 4 (25.00%)</p> <p>1</p> <p>1 / 4 (25.00%)</p> <p>1</p> <p>1 / 4 (25.00%)</p> <p>1</p>	<p>0 / 5 (0.00%)</p> <p>0</p> <p>0 / 5 (0.00%)</p> <p>0</p> <p>0 / 5 (0.00%)</p> <p>0</p> <p>0 / 5 (0.00%)</p> <p>0</p>
<p>Psychiatric disorders</p> <p>anxiety</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>depression</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>insomnia</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 5 (0.00%)</p> <p>0</p> <p>0 / 5 (0.00%)</p> <p>0</p> <p>0 / 5 (0.00%)</p> <p>0</p>	<p>2 / 4 (50.00%)</p> <p>2</p> <p>0 / 4 (0.00%)</p> <p>0</p> <p>0 / 4 (0.00%)</p> <p>0</p>	<p>0 / 5 (0.00%)</p> <p>0</p> <p>0 / 5 (0.00%)</p> <p>0</p> <p>0 / 5 (0.00%)</p> <p>0</p>
<p>Investigations</p> <p>alanine aminotransferase increased</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>aspartate aminotransferase increased</p> <p>alternative dictionary used: MedDRA 18.1</p>	<p>2 / 5 (40.00%)</p> <p>2</p>	<p>1 / 4 (25.00%)</p> <p>1</p>	<p>1 / 5 (20.00%)</p> <p>1</p>

subjects affected / exposed	2 / 5 (40.00%)	1 / 4 (25.00%)	1 / 5 (20.00%)
occurrences (all)	2	1	1
blood alkaline phosphatase increased alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	2 / 5 (40.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	2	0	0
blood bilirubin increased alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
blood calcium decreased alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 5 (20.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
blood sodium decreased alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 5 (20.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
brain natriuretic peptide increased alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	1 / 4 (25.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
c-reactive protein increased alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
ejection fraction decreased alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
neutrophil count decreased alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	2

platelet count decreased alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 4 (0.00%) 0	1 / 5 (20.00%) 1
white blood cell count decreased alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 4 (0.00%) 0	1 / 5 (20.00%) 2
Injury, poisoning and procedural complications ligament sprain alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 4 (25.00%) 1	0 / 5 (0.00%) 0
Cardiac disorders Angina pectoris alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 4 (25.00%) 1	0 / 5 (0.00%) 0
atrial fibrillation alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0
Nervous system disorders dizziness alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 4 (25.00%) 1	1 / 5 (20.00%) 1
dysgeusia alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 4 (25.00%) 1	0 / 5 (0.00%) 0
headache alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all)	3 / 5 (60.00%) 3	1 / 4 (25.00%) 1	1 / 5 (20.00%) 1

neurotoxicity alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 4 (25.00%) 1	0 / 5 (0.00%) 0
paraesthesia alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0
peripheral sensory neuropathy alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 4 (25.00%) 1	0 / 5 (0.00%) 0
Blood and lymphatic system disorders Anaemia alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all)	3 / 5 (60.00%) 3	3 / 4 (75.00%) 3	3 / 5 (60.00%) 4
febrile neutropenia alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 4 (25.00%) 1	0 / 5 (0.00%) 0
leukopenia alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0
neutropenia alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all)	3 / 5 (60.00%) 3	2 / 4 (50.00%) 2	3 / 5 (60.00%) 3
thrombocytopenia alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all)	4 / 5 (80.00%) 4	1 / 4 (25.00%) 5	1 / 5 (20.00%) 1
Gastrointestinal disorders			

abdominal pain			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	2 / 5 (40.00%)	1 / 4 (25.00%)	0 / 5 (0.00%)
occurrences (all)	2	1	0
abdominal pain upper			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	1 / 4 (25.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
ascites			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	1 / 4 (25.00%)	0 / 5 (0.00%)
occurrences (all)	0	8	0
constipation			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	2 / 5 (40.00%)	2 / 4 (50.00%)	1 / 5 (20.00%)
occurrences (all)	2	3	1
diarrhoea			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	2 / 5 (40.00%)	2 / 4 (50.00%)	2 / 5 (40.00%)
occurrences (all)	2	2	2
dry mouth			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	1 / 4 (25.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
dyspepsia			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 5 (20.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
gastrooesophageal reflux disease			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	1 / 4 (25.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
nausea			
alternative dictionary used: MedDRA 18.1			

<p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 5 (40.00%)</p> <p>2</p>	<p>4 / 4 (100.00%)</p> <p>5</p>	<p>4 / 5 (80.00%)</p> <p>9</p>
<p>rectal haemorrhage</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 5 (20.00%)</p> <p>2</p>	<p>0 / 4 (0.00%)</p> <p>0</p>	<p>0 / 5 (0.00%)</p> <p>0</p>
<p>vomiting</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>3 / 5 (60.00%)</p> <p>3</p>	<p>3 / 4 (75.00%)</p> <p>4</p>	<p>3 / 5 (60.00%)</p> <p>4</p>
<p>Hepatobiliary disorders</p> <p>jaundice</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 5 (0.00%)</p> <p>0</p>	<p>0 / 4 (0.00%)</p> <p>0</p>	<p>1 / 5 (20.00%)</p> <p>1</p>
<p>Skin and subcutaneous tissue disorders</p> <p>dry skin</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 5 (0.00%)</p> <p>0</p>	<p>0 / 4 (0.00%)</p> <p>0</p>	<p>1 / 5 (20.00%)</p> <p>1</p>
<p>erythema</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 5 (0.00%)</p> <p>0</p>	<p>2 / 4 (50.00%)</p> <p>2</p>	<p>0 / 5 (0.00%)</p> <p>0</p>
<p>night sweats</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 5 (0.00%)</p> <p>0</p>	<p>1 / 4 (25.00%)</p> <p>1</p>	<p>0 / 5 (0.00%)</p> <p>0</p>
<p>pruritus</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 5 (20.00%)</p> <p>1</p>	<p>0 / 4 (0.00%)</p> <p>0</p>	<p>0 / 5 (0.00%)</p> <p>0</p>
<p>rash</p> <p>alternative dictionary used: MedDRA 18.1</p>			

subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	2 / 4 (50.00%) 2	1 / 5 (20.00%) 1
Renal and urinary disorders			
dysuria alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 4 (25.00%) 1	0 / 5 (0.00%) 0
haematuria alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all)	2 / 5 (40.00%) 2	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0
pollakiuria alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 4 (25.00%) 1	0 / 5 (0.00%) 0
urinary incontinence alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 4 (25.00%) 1	0 / 5 (0.00%) 0
Musculoskeletal and connective tissue disorders			
arthralgia alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 4 (25.00%) 5	0 / 5 (0.00%) 0
arthritis alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 4 (25.00%) 1	0 / 5 (0.00%) 0
back pain alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 4 (0.00%) 0	1 / 5 (20.00%) 1
bone pain alternative dictionary used: MedDRA 18.1			

subjects affected / exposed	0 / 5 (0.00%)	1 / 4 (25.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Muscle spasms			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 5 (20.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
musculoskeletal chest pain			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	1 / 4 (25.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
myalgia			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	1 / 4 (25.00%)	2 / 5 (40.00%)
occurrences (all)	0	1	2
pain in extremity			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	1 / 4 (25.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Infections and infestations			
folliculitis			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 5 (20.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
nasopharyngitis			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
pneumonia			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
urinary tract infection			
alternative dictionary used: MedDRA 18.1			

subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0
Metabolism and nutrition disorders			
decreased appetite			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 5 (20.00%)	2 / 4 (50.00%)	2 / 5 (40.00%)
occurrences (all)	1	2	2
Dehydration			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 5 (20.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
hyperglycaemia			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	2 / 5 (40.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	2	0	0
hypoalbuminaemia			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	3 / 5 (60.00%)	1 / 4 (25.00%)	1 / 5 (20.00%)
occurrences (all)	3	1	1
hypocalcaemia			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 5 (20.00%)	0 / 4 (0.00%)	1 / 5 (20.00%)
occurrences (all)	1	0	1
hypokalaemia			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 5 (0.00%)	0 / 4 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
hypomagnesaemia			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 5 (20.00%)	0 / 4 (0.00%)	0 / 5 (0.00%)
occurrences (all)	2	0	0
hyponatraemia			
alternative dictionary used: MedDRA 18.1			

subjects affected / exposed	0 / 5 (0.00%)	1 / 4 (25.00%)	1 / 5 (20.00%)
occurrences (all)	0	1	1

Non-serious adverse events	Phase 2: 300 mg LY2157299 + Gemcitabine	Phase 2: Placebo + Gemcitabine	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	100 / 103 (97.09%)	49 / 52 (94.23%)	
General disorders and administration site conditions			
asthenia			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	36 / 103 (34.95%)	17 / 52 (32.69%)	
occurrences (all)	72	30	
chills			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	10 / 103 (9.71%)	4 / 52 (7.69%)	
occurrences (all)	12	6	
early satiety			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 103 (0.00%)	0 / 52 (0.00%)	
occurrences (all)	0	0	
face oedema			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 103 (0.00%)	0 / 52 (0.00%)	
occurrences (all)	0	0	
fatigue			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	21 / 103 (20.39%)	9 / 52 (17.31%)	
occurrences (all)	28	14	
localised oedema			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 103 (0.00%)	0 / 52 (0.00%)	
occurrences (all)	0	0	
mucosal inflammation			
alternative dictionary used: MedDRA 18.1			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>1 / 103 (0.97%)</p> <p>1</p> <p>4 / 52 (7.69%)</p> <p>4</p>			
<p>oedema peripheral</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>23 / 103 (22.33%)</p> <p>33</p> <p>12 / 52 (23.08%)</p> <p>15</p>			
<p>pain</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>1 / 103 (0.97%)</p> <p>1</p> <p>2 / 52 (3.85%)</p> <p>2</p>			
<p>peripheral swelling</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>0 / 103 (0.00%)</p> <p>0</p> <p>0 / 52 (0.00%)</p> <p>0</p>			
<p>pyrexia</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>38 / 103 (36.89%)</p> <p>93</p> <p>11 / 52 (21.15%)</p> <p>17</p>			
<p>Reproductive system and breast disorders</p> <p>pelvic pain</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>1 / 103 (0.97%)</p> <p>1</p> <p>1 / 52 (1.92%)</p> <p>1</p>			
<p>Respiratory, thoracic and mediastinal disorders</p> <p>cough</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>7 / 103 (6.80%)</p> <p>10</p> <p>2 / 52 (3.85%)</p> <p>2</p> <p>dyspnoea</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>6 / 103 (5.83%)</p> <p>7</p> <p>4 / 52 (7.69%)</p> <p>4</p> <p>epistaxis</p> <p>alternative dictionary used: MedDRA 18.1</p>			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>oropharyngeal pain</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 103 (1.94%)</p> <p>2</p> <p>0 / 103 (0.00%)</p> <p>0</p>	<p>0 / 52 (0.00%)</p> <p>0</p> <p>0 / 52 (0.00%)</p> <p>0</p>	
<p>Psychiatric disorders</p> <p>anxiety</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>depression</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>insomnia</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>6 / 103 (5.83%)</p> <p>6</p> <p>1 / 103 (0.97%)</p> <p>1</p> <p>6 / 103 (5.83%)</p> <p>6</p>	<p>4 / 52 (7.69%)</p> <p>4</p> <p>4 / 52 (7.69%)</p> <p>4</p> <p>3 / 52 (5.77%)</p> <p>4</p>	
<p>Investigations</p> <p>alanine aminotransferase increased</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>aspartate aminotransferase increased</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>blood alkaline phosphatase increased</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>blood bilirubin increased</p> <p>alternative dictionary used: MedDRA 18.1</p>	<p>10 / 103 (9.71%)</p> <p>14</p> <p>8 / 103 (7.77%)</p> <p>14</p> <p>3 / 103 (2.91%)</p> <p>3</p>	<p>3 / 52 (5.77%)</p> <p>6</p> <p>2 / 52 (3.85%)</p> <p>4</p> <p>1 / 52 (1.92%)</p> <p>1</p>	

subjects affected / exposed	8 / 103 (7.77%)	0 / 52 (0.00%)
occurrences (all)	8	0
blood calcium decreased		
alternative dictionary used: MedDRA 18.1		
subjects affected / exposed	0 / 103 (0.00%)	0 / 52 (0.00%)
occurrences (all)	0	0
blood sodium decreased		
alternative dictionary used: MedDRA 18.1		
subjects affected / exposed	0 / 103 (0.00%)	0 / 52 (0.00%)
occurrences (all)	0	0
brain natriuretic peptide increased		
alternative dictionary used: MedDRA 18.1		
subjects affected / exposed	0 / 103 (0.00%)	0 / 52 (0.00%)
occurrences (all)	0	0
c-reactive protein increased		
alternative dictionary used: MedDRA 18.1		
subjects affected / exposed	2 / 103 (1.94%)	3 / 52 (5.77%)
occurrences (all)	2	4
ejection fraction decreased		
alternative dictionary used: MedDRA 18.1		
subjects affected / exposed	0 / 103 (0.00%)	0 / 52 (0.00%)
occurrences (all)	0	0
neutrophil count decreased		
alternative dictionary used: MedDRA 18.1		
subjects affected / exposed	11 / 103 (10.68%)	5 / 52 (9.62%)
occurrences (all)	31	10
platelet count decreased		
alternative dictionary used: MedDRA 18.1		
subjects affected / exposed	17 / 103 (16.50%)	8 / 52 (15.38%)
occurrences (all)	38	14
white blood cell count decreased		
alternative dictionary used: MedDRA 18.1		
subjects affected / exposed	9 / 103 (8.74%)	3 / 52 (5.77%)
occurrences (all)	16	3

Injury, poisoning and procedural complications ligament sprain alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all)	0 / 103 (0.00%) 0	0 / 52 (0.00%) 0	
Cardiac disorders Angina pectoris alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all) atrial fibrillation alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all)	0 / 103 (0.00%) 0 1 / 103 (0.97%) 1	0 / 52 (0.00%) 0 3 / 52 (5.77%) 3	
Nervous system disorders dizziness alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all) dysgeusia alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all) headache alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all) neurotoxicity alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all) paraesthesia alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all)	6 / 103 (5.83%) 7 2 / 103 (1.94%) 2 6 / 103 (5.83%) 6 0 / 103 (0.00%) 0 4 / 103 (3.88%) 4	4 / 52 (7.69%) 7 0 / 52 (0.00%) 0 6 / 52 (11.54%) 8 0 / 52 (0.00%) 0 1 / 52 (1.92%) 1	

peripheral sensory neuropathy alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all)	1 / 103 (0.97%) 1	1 / 52 (1.92%) 1	
Blood and lymphatic system disorders			
Anaemia alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all)	44 / 103 (42.72%) 95	28 / 52 (53.85%) 35	
febrile neutropenia alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all)	0 / 103 (0.00%) 0	0 / 52 (0.00%) 0	
leukopenia alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all)	4 / 103 (3.88%) 6	3 / 52 (5.77%) 8	
neutropenia alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all)	34 / 103 (33.01%) 76	17 / 52 (32.69%) 42	
thrombocytopenia alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all)	29 / 103 (28.16%) 83	13 / 52 (25.00%) 21	
Gastrointestinal disorders			
abdominal pain alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all)	26 / 103 (25.24%) 38	12 / 52 (23.08%) 16	
abdominal pain upper alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all)	12 / 103 (11.65%) 16	5 / 52 (9.62%) 6	
ascites			

alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	13 / 103 (12.62%)	1 / 52 (1.92%)	
occurrences (all)	14	1	
constipation			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	30 / 103 (29.13%)	15 / 52 (28.85%)	
occurrences (all)	31	22	
diarrhoea			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	23 / 103 (22.33%)	12 / 52 (23.08%)	
occurrences (all)	56	26	
dry mouth			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	3 / 103 (2.91%)	1 / 52 (1.92%)	
occurrences (all)	3	1	
dyspepsia			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	8 / 103 (7.77%)	3 / 52 (5.77%)	
occurrences (all)	8	5	
gastrooesophageal reflux disease			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	2 / 103 (1.94%)	5 / 52 (9.62%)	
occurrences (all)	2	5	
nausea			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	39 / 103 (37.86%)	17 / 52 (32.69%)	
occurrences (all)	69	30	
rectal haemorrhage			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	0 / 103 (0.00%)	0 / 52 (0.00%)	
occurrences (all)	0	0	
vomiting			
alternative dictionary used: MedDRA 18.1			

subjects affected / exposed occurrences (all)	27 / 103 (26.21%) 57	19 / 52 (36.54%) 26	
Hepatobiliary disorders jaundice alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all)	3 / 103 (2.91%) 3	1 / 52 (1.92%) 1	
Skin and subcutaneous tissue disorders dry skin alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all) erythema alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all) night sweats alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all) pruritus alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all) rash alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all)	5 / 103 (4.85%) 6 2 / 103 (1.94%) 2 2 / 103 (1.94%) 2 5 / 103 (4.85%) 6 5 / 103 (4.85%) 7	2 / 52 (3.85%) 2 2 / 52 (3.85%) 2 2 / 52 (3.85%) 6 2 / 52 (3.85%) 2 5 / 52 (9.62%) 9	
Renal and urinary disorders dysuria alternative dictionary used: MedDRA 18.1 subjects affected / exposed occurrences (all) haematuria alternative dictionary used: MedDRA 18.1	4 / 103 (3.88%) 4	0 / 52 (0.00%) 0	

<p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 103 (1.94%)</p> <p>2</p>	<p>0 / 52 (0.00%)</p> <p>0</p>	
<p>pollakiuria</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 103 (0.00%)</p> <p>0</p>	<p>1 / 52 (1.92%)</p> <p>1</p>	
<p>urinary incontinence</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 103 (0.00%)</p> <p>0</p>	<p>0 / 52 (0.00%)</p> <p>0</p>	
<p>Musculoskeletal and connective tissue disorders</p> <p>arthralgia</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>5 / 103 (4.85%)</p> <p>6</p>	<p>0 / 52 (0.00%)</p> <p>0</p>	
<p>arthritis</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 103 (0.97%)</p> <p>1</p>	<p>0 / 52 (0.00%)</p> <p>0</p>	
<p>back pain</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>8 / 103 (7.77%)</p> <p>9</p>	<p>4 / 52 (7.69%)</p> <p>4</p>	
<p>bone pain</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 103 (0.00%)</p> <p>0</p>	<p>1 / 52 (1.92%)</p> <p>1</p>	
<p>Muscle spasms</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 103 (0.97%)</p> <p>1</p>	<p>2 / 52 (3.85%)</p> <p>2</p>	
<p>musculoskeletal chest pain</p> <p>alternative dictionary used: MedDRA 18.1</p>			

<p>subjects affected / exposed</p> <p>0 / 103 (0.00%)</p> <p>0 / 52 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>0</p>			
<p>myalgia</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>6 / 103 (5.83%)</p> <p>0 / 52 (0.00%)</p> <p>occurrences (all)</p> <p>7</p> <p>0</p>			
<p>pain in extremity</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>4 / 103 (3.88%)</p> <p>1 / 52 (1.92%)</p> <p>occurrences (all)</p> <p>6</p> <p>2</p>			
<p>Infections and infestations</p> <p>folliculitis</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>0 / 103 (0.00%)</p> <p>0 / 52 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>0</p>			
<p>nasopharyngitis</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>7 / 103 (6.80%)</p> <p>1 / 52 (1.92%)</p> <p>occurrences (all)</p> <p>9</p> <p>1</p>			
<p>pneumonia</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>1 / 103 (0.97%)</p> <p>4 / 52 (7.69%)</p> <p>occurrences (all)</p> <p>1</p> <p>4</p>			
<p>urinary tract infection</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>6 / 103 (5.83%)</p> <p>3 / 52 (5.77%)</p> <p>occurrences (all)</p> <p>8</p> <p>4</p>			
<p>Metabolism and nutrition disorders</p> <p>decreased appetite</p> <p>alternative dictionary used: MedDRA 18.1</p> <p>subjects affected / exposed</p> <p>30 / 103 (29.13%)</p> <p>13 / 52 (25.00%)</p> <p>occurrences (all)</p> <p>42</p> <p>18</p>			
<p>Dehydration</p> <p>alternative dictionary used: MedDRA 18.1</p>			

subjects affected / exposed	1 / 103 (0.97%)	3 / 52 (5.77%)	
occurrences (all)	2	3	
hyperglycaemia			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	8 / 103 (7.77%)	4 / 52 (7.69%)	
occurrences (all)	14	5	
hypoalbuminaemia			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	4 / 103 (3.88%)	1 / 52 (1.92%)	
occurrences (all)	4	1	
hypocalcaemia			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	6 / 103 (5.83%)	2 / 52 (3.85%)	
occurrences (all)	7	2	
hypokalaemia			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	13 / 103 (12.62%)	2 / 52 (3.85%)	
occurrences (all)	17	2	
hypomagnesaemia			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	1 / 103 (0.97%)	2 / 52 (3.85%)	
occurrences (all)	1	2	
hyponatraemia			
alternative dictionary used: MedDRA 18.1			
subjects affected / exposed	3 / 103 (2.91%)	2 / 52 (3.85%)	
occurrences (all)	3	2	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
01 March 2013	<p>After completing the Phase1b part of this study and based on additional safety and PD information from other studies with LY2157299 (see 2012 LY2157299 IB), the study was amended for the following reasons:</p> <p>No Pharmacodynamic (PD) changes in gene expression profiles of peripheral blood mononuclear cell (PBMCs)/whole blood in patients treated with LY2157299 were seen, and therefore, there is no longer a requirement for collection of additional blood samples. All such PD assessments and their collection will be stopped, and no evaluation will be performed on all patients.</p> <p>Protocol clarifications added per suggestions from sites and investigators, including clarification on bilirubin levels, the type of chest CT scans recommended for this study, the range of allowable chemotherapies during the adjuvant treatment.</p>
18 December 2015	<p>Amendment (c): This study was amended to enable all patients who are still in the study (either on study treatment, in short-term follow-up period or in long-term follow-up period) to be followed for overall survival after the study is considered complete for the primary objective. Minor editorial changes were made but not listed.</p>

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported